

case report **90**

Center for Health Sciences  
University of Wisconsin at Madison

*A case is presented of the treatment of a unipolar delusional depression with electroconvulsive therapy. During the course of the treatments, the patient suddenly became extremely confused, bizarre, and agitated. The decision as to whether to continue the ECT rested on understanding this response. The decision-making process, possible explanations, and preventive measures are discussed.*

## an organic psychosis associated with electroconvulsive therapy

John R. Marshall, M.D., Ned G. Kalin, M.D., and Alice M. Tariot, M.D.

Transient organic brain syndromes are commonly seen in patients undergoing electroconvulsive therapy. Usually the symptoms are minor, clear rapidly, and do not present difficult management problems. Occasionally the severity of these symptoms presents very difficult dilemmas for the treatment team.

The patient, a 54-year-old, married, insurance salesman and father of two children had been hospitalized five years earlier with a diagnosis of "psychotic depression and mild organic brain damage." He had been treated successfully with a course of eight electroconvulsive treatments, and only mild confusion was noted after each of these treatments. Subsequently, he was maintained on amitriptyline HCl and chlorpromazine HCl (doses unknown) for several months and returned to work.

He remained well until approximately one year prior to this admission, when he began to experience difficulties at work. Four months prior to admission he had been fired because of poor performance. His depression worsened, and his alcohol intake increased substantially, to three to four martinis and six beers per day. He denied a history of blackout spells, previous withdrawal symptoms, or social sequelae of alcoholism. There was no history of manic episodes nor family history of any psychiatric illness. He and his wife described some marital difficulties during the previous six years, but there were no other social or psychological stresses which we could

identify as possibly precipitating the present episode.


Two months earlier he was hospitalized for the surgical removal of renal stones. During his convalescence at home, he became increasingly depressed, with frequent crying spells, obsessive thought and ruminations, insomnia, anorexia (with a 10-pound weight loss), and agitation. At that point he was admitted to another hospital.

Their records revealed that upon admission the patient was having "paranoid ideation, self-deprecating verbalization, impaired reality testing, and auditory hallucinations." He was begun on trifluoperazine HCl 30 mg per day with minimal response after 10 days. Chlorpromazine was begun and eight days later amitriptyline HCl added. His thought disorder cleared on these medications but depressive features remained prominent. Upon transfer (for financial reasons) the diagnosis was "recurrent psychotic depression." Medications consisted of amitriptyline HCl 100 mg b.i.d., chlorpromazine HCl 150 mg t.i.d., and triamterene 50 mg/hydrochlorothiazide 25 mg (for prevention of renal calculi).

Upon his admission to our hospital, the patient was described as a middle-aged, greying man, unshaven but neatly dressed. Though cooperative, he exhibited psychomotor retardation and slow, soft speech. He also seemed sedated. Thought processes were rational, coherent, and goal-directed, though occasionally he was circumstantial and tangential. There was no evidence of loosened associations, delusions, or hallucinations.



# DOES HIS TRANQUILIZER NEED A "TRANQUILIZER"?





# **Drug-induced akathisia, tremor, and other extrapyramidal side effects are minimal with Mellaril® (thioridazine)... antiparkinsonian agents are seldom required**

If the medication literally contains jitteriness for the patient, if he can't keep still while he's sitting, can't keep steady while he's at work or recreation—that's hardly helpful to him or the physician. Yet akathisia and other extrapyramidal reactions are quite common with many major tranquilizers, often even requiring antiparkinsonian agents to counter these unwanted drug-induced symptoms.

Mellaril (thioridazine) has the lowest incidence of extrapyramidal reactions of all major tranquilizers.<sup>1</sup> Seldom is it necessary to use concomitant antiparkinsonian drugs, which can cause side effects of their own and contribute to the problem of noncompliance. Mellaril (thioridazine) is contraindicated in patients with hypertensive or hypotensive heart disease of extreme degree.

Your own observations have probably told you how well many patients get along on Mellaril therapy, how effectively it helps in the management of psychotic symptoms.

1. Byck R: Drugs and the treatment of psychiatric disorders, in Goodman LS, Gilman A (eds): *The Pharmacological Basis of Therapeutics*, ed 5. New York, Macmillan Publishing Co, Inc, 1975, pp 170-171.

## **Mellaril®** **(thioridazine)**

TABLETS: 50 mg, 100 mg, 150 mg, and 200 mg thioridazine HCl, USP

MELLARIL-S™ (thioridazine) SUSPENSION, per 5 ml:  
thioridazine base equivalent to 100 mg thioridazine HCl, USP

### **kind to many patients with psychotic symptoms**

For Brief Summary, please see following page.



## Mellaril® (thioridazine)

Before prescribing or administering, see Sandoz literature for full product information. The following is a brief summary.

**Contraindications:** Severe central nervous system depression, comatose states from any cause, hypertensive or hypotensive heart disease of extreme degree.

**Warnings:** Administer cautiously to patients who have previously exhibited a hypersensitivity reaction (e.g., blood dyscrasias, jaundice) to phenothiazines. Phenothiazines are capable of potentiating central nervous system depressants (e.g., anesthetics, opiates, alcohol, etc.) as well as atropine and phosphorus insecticides; carefully consider benefit versus risk in less severe disorders. During pregnancy, administer only when the potential benefits exceed the possible risks to mother and fetus.

**Precautions:** There have been infrequent reports of leukopenia and/or agranulocytosis and convulsive seizures. In epileptic patients, anticonvulsant medication should also be maintained. Pigmentary retinopathy, observed primarily in patients receiving larger than recommended doses, is characterized by diminution of visual acuity, brownish coloring of vision, and impairment of night vision; the possibility of its occurrence may be reduced by remaining within recommended dosage limits. Administer cautiously to patients participating in activities requiring complete mental alertness (e.g., driving), and increase dosage gradually. Orthostatic hypotension is more common in females than in males. Do not use epinephrine in treating drug-induced hypotension since phenothiazines may induce a reversed epinephrine effect on occasion. Daily doses in excess of 300 mg should be used only in severe neuropsychiatric conditions.

**Adverse Reactions:** *Central Nervous System*—Drowsiness, especially with large doses, early in treatment; infrequently, pseudoparkinsonism and other extrapyramidal symptoms; rarely, nocturnal confusion, hyperreflexia, lethargy, psychotic reactions, restlessness, and headache. *Autonomic Nervous System*—Dryness of mouth, blurred vision, constipation, nausea, vomiting, diarrhea, nasal stuffiness, and pallor. *Endocrine System*—Galactorrhea, breast engorgement, amenorrhea, inhibition of ejaculation, and peripheral edema. *Skin*—Dermatitis and skin eruptions of the urticarial type, photosensitivity. *Cardiovascular System*—ECG changes (see *Cardiovascular Effects* below). *Other*—Rare cases described as parotid swelling.

It should be noted that efficacy, indications and untoward effects have varied with the different phenothiazines. It has been reported that old age lowers the tolerance for phenothiazines; the most common neurologic side effects are parkinsonism and akathisia, and the risk of agranulocytosis and leukopenia increases. The following reactions have occurred with phenothiazines and should be considered whenever one of these drugs is used. *Autonomic Reactions*—Miosis, oblation, anorexia, paralytic ileus. *Cutaneous Reactions*—Erythema, exfoliative dermatitis, contact dermatitis. *Blood Dyscrasias*—Agranulocytosis, leukopenia, eosinophilia, thrombocytopenia, anemia, aplastic anemia, pancytopenia. *Allergic Reactions*—Fever, laryngeal edema, angioneurotic edema, asthma. *Hepatotoxicity*—Jaundice, biliary stasis. *Cardiovascular Effects*—Changes in terminal portion of electrocardiogram, including prolongation of Q-T interval, lowering and inversion of T-wave, and appearance of a wave tentatively identified as a bifid T or a U wave have been observed with phenothiazines, including Mellaril (thioridazine); these appear to be reversible and due to altered repolarization, not myocardial damage. While there is no evidence of a causal relationship between these changes and significant disturbance of cardiac rhythm, several sudden and unexpected deaths apparently due to cardiac arrest have occurred in patients showing characteristic electrocardiographic changes while taking the drug. While proposed, periodic electrocardiograms are not regarded as predictive. Hypotension, rarely resulting in cardiac arrest. *Extrapyramidal Symptoms*—Akathisia, agitation, motor restlessness, dystonic reactions, trismus, lorticolis, opisthotonus, oculogyric crises, tremor, muscular rigidity, and akinesia. *Persistent Tardive Dyskinesia*—Persistent and sometimes irreversible tardive dyskinesia, characterized by rhythmical involuntary movements of the tongue, face, mouth, or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements) and sometimes of extremities may occur on long-term therapy or after discontinuation of therapy, the risk being greater in elderly patients on high-dose therapy, especially females; if symptoms appear, discontinue all antipsychotic agents. Syndrome may be masked if treatment is reinstituted, dosage is increased, or antipsychotic agent is switched. Fine vermicular movements of tongue may be an early sign, and syndrome may not develop if medication is stopped at that time. *Endocrine Disturbances*—Menstrual irregularities, altered libido, gynecomastia, lactation, weight gain, edema, false positive pregnancy tests. *Urinary Disturbances*—Retention, incontinence. *Others*—Hyperpyrexia; behavioral effects suggestive of a paradoxical reaction, including excitement, bizarre dreams, aggravation of psychoses, and toxic confusional states; following long-term treatment, a peculiar skin-eye syndrome marked by progressive pigmentation of skin or conjunctiva and/or accompanied by discoloration of exposed sclera and cornea; stellate or irregular opacities of anterior lens and cornea; systemic lupus erythematosus-like syndrome. SDZ 8-222



SANDOZ PHARMACEUTICALS, EAST HANOVER, N.J. 07936

His mood was profoundly depressed, and his affect appropriate for thought content. He denied suicidal ideation, although he admitted to such in the past. He was oriented to person, place, and year but not to day or date. He appeared to concentrate adequately, performing serial sevens slowly but without error. Intelligence was judged to be normal. Short-term and remote memory were intact, except for difficulty in recalling the events of the first three weeks of hospitalization. Judgment seemed intact.

Physical examination, including neurologic exam, was entirely within normal limits. Routine laboratory studies including electrolytes were unremarkable.

### Treatment

Our initial impression was that this patient was suffering from a recurrent unipolar depression, the delusional portion of which had resolved. There was also a history of significant alcohol abuse. We felt that minor cognitive difficulties noted in the mental status exam probably resulted from his extremely depressed state, rather than from an organic brain syndrome.

Because of excessive sedation and some orthostatic hypotension, the chlorpromazine HCl was reduced while levels of amitriptyline HCl were continued. On the third hospital day (chlorpromazine HCl 150 mg per day) the patient's condition changed rather suddenly. He began ruminating, became quite agitated, and was unable to tell whether it was morning or afternoon. He reported auditory hallucinations commanding him to hurt himself. He banged his head on the floor, attempted to pull his hair out, and talked of poking his eyes out. He required intermittent seclusion and restraints for self-protection. When not restrained, he curled in a fetal position on the floor for long periods of time.

At this time rapid tranquilization with thiothixene was begun for behavioral control. Over the next few days there was a moderate decrease in his auditory hallucinations and in his agitated and self-destructive behaviors, but his guilty ruminations, delusions, and regressed behavior seemed unaffected. It was not possible to further increase his thiothixene (45 mg per day) or amitriptyline because of the symptomatic orthostatic hypotension. Because of this, nondominant unilateral electroconvulsive therapy was begun on the 11th hospital day and planned for alternate days three times a week. His amitriptyline HCl was reduced and discontinued, but the thiothixene was continued for behavioral control.

During the routine workup for the ECT, skull films had revealed a double floor to the sella turcica. Tomograms tended to confirm this interpretation. In the absence of symptoms of pituitary disease, we elected to proceed.

After each of the first three treatments the patient was so agitated and belligerent that he required physical restraint and intravenous diazepam 5-10 mg for sedation. Upon awakening minutes to several hours later, the patient showed no signs of agitation and confusion. How-



ever, later in the day, after the third treatment, he again became agitated and confused. He was disoriented to time and place. His speech was rambling, incoherent, and he demonstrated echolalia. His behavior was bizarre and inappropriate. For example, he put his cigarette out on the television, chewed on a toy, and ate from other patient's trays. This clinical picture differed from that preceding ECT in that the affect was labile and non-depressed — he often acted silly. Because of the severity of this clinical state and its persistence over the next few days, we became concerned, wondering if this represented something other than those changes usually associated with electroshock therapy.

A neurology consultant felt that a focal brain lesion was unlikely but suggested computerized tomography. Thiothixene was also stopped in order to determine whether drug toxicity might be a contributing factor. The scan was read as "minimal cerebral atrophy consistent with the patient's age and history of alcohol intake." On the basis of these findings the ECT treatments were continued. As the treatment progressed, the profoundly bizarre and agitated behavior diminished slightly but the cognitive defects remained. Evaluation of his depressive signs and symptoms was impossible; nonetheless, the original plan of eight ECT treatments was completed.

During the week following treatment, the patient's mood brightened and his irritability, confusion, and disorientation subsided, although memory difficulties remained prominent. At discharge, two weeks later, there were no signs of depression, he was nondelusional, and the mental status examination revealed no evidence of organic dysfunction. Neuropsychological testing demonstrated "bright normal to superior functioning on psychometric, memory, attentional, and motor mea-

sures." The patient was discharged on imipramine HCl 100 mg at bedtime. Follow-up at three months revealed that he was doing well.

## Discussion

This was a patient with depressive and psychotic symptoms, who was resistant to psychotropic medication (or could not be given adequate amounts) and for whom electroconvulsive treatment was instituted. Our diagnosis was recurrent unipolar depression of psychotic proportions. Soon after ECT was begun, the patient became agitated, disorganized, and demonstrated extreme intellectual deterioration — confronting us with important treatment decisions.

There were a number of possible explanatory considerations. One was that the renewed agitation and confused behavior were related to a psychotropic drug the patient was receiving — i.e. that the agitated behavior may have reflected an idiosyncratic response to the thiothixene. However, we felt that this was unlikely, and that the thiothixene was needed (45 mg per day) to control the patient's self-destructive tendencies and lessen the need for constant restraint. There has been concern expressed over the combination of ECT and neuroleptic drugs (also antidepressants), but this is generally related to hypotensive propensities and adverse interactions with the barbiturates during the treatments, rather than to an intrinsic adverse interaction between ECT and a specific drug.<sup>1</sup> The likelihood of an anticholinergic psychosis was entertained but no signs of anticholinergic toxicity were found.

We were concerned about whether an undiagnosed cerebral lesion was being aggravated by the ECT. This phenomena has been reported by others, and a brain

## SELF-ASSESSMENT (answers on page 40)

Choose the correct response(s) to each of the following:

- Possible explanations for agitation, disorganization, and cognitive deterioration during a course of ECT are:
  - uncovering an underlying schizophrenia.
  - organic-psychotic syndrome secondary to ECT.
  - precipitation of a manic episode.
  - underlying organic central nervous system pathology.
- Regressive ECT:
  - involves giving the patient more than one treatment per day.
  - is used to treat severely regressed hysterical patients.
  - is more beneficial than antipsychotic agents for schizophrenic patients.
  - can produce a severe dementia.
- Methods that may help minimize confusion and amnesia during a course of ECT include:
  - unilateral dominant placement of electrodes.
  - unilateral nondominant placement of electrodes.
  - supplemental vitamin B<sub>12</sub>.
  - I. V. drip method for the administration of drugs for anesthesia and relaxation.
- Moderate cognitive and orientation disturbances are always indicative of an organic brain syndrome.
  - True
  - False
- Post-ECT excitement states are best treated with:
  - oral barbiturate.
  - oral diazepam.
  - physical restraint and patience.
  - I. V. diazepam.
  - I. V. barbiturate.
- Which of the following statements about the use of psychotropic drugs with ECT are accurate?
  - Use of tricyclic antidepressants during a course of ECT increases the likelihood for positive response.
  - Antipsychotic agents should always be discontinued during a course of ECT.
  - Psychotropic drugs that can cause orthostatic hypotension may synergize with the I.V. barbiturates in this manner.
  - The use of tricyclic antidepressants after a course of ECT may prove to be prophylactic for the recurrence of an affective disorder.



tumor is, of course, a definite contraindication to ECT, with risk of fatality.<sup>2</sup> The nonlocalized scan findings and discussions with our neurologic consultants helped allay these fears.

It was also possible that the ECT had activated an underlying psychosis (perhaps schizophrenia). This is described as occurring most often in quiet, blocked, or depressed schizophrenics, in whom an acute delusional hallucinatory syndrome emerges after the first few treatments.<sup>3</sup> These patients have often been considered depressed, and following ECT an unsuspected schizophrenic psychosis becomes overt. Halpern stated that in this manner ECT can serve as a diagnostic aid in schizophrenia.<sup>4</sup> Slater and Roth, discussing depressed patients, also noted that concealed symptoms may emerge from ECT, revealing the patient as "an unmistakable schizophrenic."<sup>5</sup> However, considering our patient's age, premorbid personality, and the course of the illness, this did not seem to be the case.

The most likely explanation of this behavior was that it was an exaggeration of effects normally seen with electroconvulsive therapy. We postulate that in view of the patient's history of alcoholism and the "minimal cerebral atrophy" demonstrated on the scan, there may have been a reduced threshold or increased sensitivity to those effects normally seen after treatments. These effects — some immediate confusion, and an amnesia which usually clears up in one to two hours — may become more severe as treatment progresses. There is often mild emotional disturbance and the patient may appear dull or silly. This induction of organic impairment has been utilized by some to treat schizophrenic patients. The technique, "regressive ECT," requires multiple daily treatments to induce an organic psychosis.<sup>6,7</sup> Particularly beneficial clinical responses to this form of treatment, compared with usual methods, have not been substantiated, and prolonged severe dementia has been reported.<sup>8-9</sup>

It is not unusual for individual treatments to be followed by periods of postconvulsive excitement occasionally leading to dangerous aggressiveness. This kind of circumscribed agitation was seen following our patient's first three treatments. As in cases described by others, it was brief, being successfully treated with I.V. diazepam.<sup>3</sup>

In 1945, Kalinowsky reported an organic psychotic syndrome occurring during electroconvulsive therapy,<sup>10</sup> and the phenomena has been accepted in the literature. This organic-psychotic reaction takes a variety of forms, with Korsakoff-like pictures being most frequent. Patients are described as bewildered, often showing severe psychomotor excitement with delusional fears and hallucinations. These organic reactions seem to be differentiated from other psychotic syndromes in that there is more organic blurring of consciousness, greater emotional lability, more flight of delusions, and more vividness to the hallucinations. In general, the patients seem to be less coherent, and there is severe impairment of in-

tellectual function with a tendency to perseveration and circumstantiality. Organic signs dominate the picture. Though the presence of delusions or hallucinations in our patient was difficult to ascertain, the extreme cognitive dysfunction was remarkable. Being reassured by the description of these organic psychoses, we were able to complete eight ECT treatments, the agreed upon goal. Kalinowsky and Hippus warned that a frequent mistake is the premature discontinuation of treatment if the organic reaction is mistaken for an aggravation of the patient's original psychosis.<sup>2</sup> Conversely, overtreatment may occur if the reaction is felt to be part of the patient's primary illness. By disappearing spontaneously within a week to 10 days following the last treatment, the organic reaction in this case confirmed the earlier experience of Kalinowsky and Hippus.

We speculated in retrospect about whether this response could have been predicted. If so, we could have better prepared the family and our staff, and perhaps minimized the reaction. We knew the patient had exhibited mild confusion after his treatments five years ago, but this is not unusual. Documentation for the diagnosis upon transfer of "mild organic brain syndrome" was lacking, and the minor signs of initial mental status examination which might have been attributed to an organic brain syndrome are commonly seen in delusional unipolar depressions.<sup>11</sup> We are aware of no studies which specifically discuss organic reactions occurring more often or with greater severity in chronic alcoholics being treated with ECT. There are several papers discussing ECT in patients with various kinds of CNS disease.<sup>12-14</sup> None of these papers indicate an exaggerated organic response to ECT therapy is expected. Elmore and Sugarman suggest that such a prediction may be based upon a past history of prolonged schizoid or borderline adjustment, evidence in psychological testing, or poorly organized ego structure, such as faulty contact with reality or loosening of associations.<sup>15</sup> These observations would not have been pertinent in this case.

If we had been prewarned, several measures might have been useful. Unilateral ECT over the nondominant hemisphere was used for this patient but not specifically as a prophylactic measure. Unilateral ECT has been reported to be accompanied by less amnesia and confusion than the conventional bilateral ECT.<sup>16</sup> In general, desirable clinical effects for the unilateral and bilateral ECT are found to be equivalent, although there is some difference of opinion regarding this.<sup>17</sup>

Kalinowsky described the use of an intravenous drip method of administering ultrashort-acting barbiturates prior to ECT.<sup>18</sup> Utilized in this manner, the amount of barbiturate required to introduce amnesia is one-half to one-third the amount necessary for induction when rapid intravenous injection is used. This method also decreases the amount of succinylcholine chloride needed to achieve maximal relaxation. When administered with continuous oxygen, this method may result in a reduced period of apnea, thus ensuring better brain oxygenation.



## REFERENCES

1. Ayd, F. J., Jr. "ECT and Psychotropic Drugs," *Rational Psychopharmacotherapy in the Right to Treatment*. Chapter 10. Ayd Medical Communications, Baltimore, 1975.
2. Kalinowsky, L. B., and H. Hippus. *Pharmacological, Convulsive and Other Somatic Treatments in Psychiatry*. Grune & Stratton, New York, 1969.
3. Freedman, D. X., and J. E. Dyrud. "Electric and Other Convulsive Treatments," *American Handbook of Psychiatry*, 2nd edition, Vol. 5, Chap. 27. Basic Books Inc., New York, 1975.
4. Halpern, L. "Electroshock as a Diagnostic Aid in Schizophrenia," *Monatsschr. Psychiatry Neurology*, Vol. 118, 1949, pp. 61-64.
5. Slater, E., and M. Roth. *Clin. Psychiatry*. The Williams & Wilkins Co., Baltimore, 1969.
6. Glueck, B. C., H. Reiss and L. E. Bernard. "Regressive Electric Shock Therapy," *Psychiatr. Q.*, Vol. 31, 1957, pp. 117-135.
7. Murillo, L. G., and J. E. Exner, Jr. "The Effects of Regressive ECT with Process Schizophrenia," *Am. J. Psychiatry*, Vol. 30, 1973, pp. 269-273.
8. Fink, M., and R. Abrams. "Answers to Questions Frequently Asked about ECT," *Semin. Psychiatry*, Vol. 4, 1972, pp. 33-38.
9. Regenstien, Q. R., B. J. Murawski, and R. P. Engle. "A Case of Prolonged, Reversible Dementia Associated with Abuse of Convulsive Therapy," *J. Nerv. Ment. Dis.*, Vol. 161, 1975, pp. 200-203.
10. Kalinowsky, L. B. "Organic Psychotic Syndromes Occurring during Electroconvulsive Therapy," *Arch. Neurol. Psychiatry*, Vol. 53, 1945, pp. 269-273.
11. Nelson, J. C., and M. B. Bowers, Jr. "Delusional Unipolar Depression," *Arch. Gen. Psychiatry*, Vol. 35, 1978, pp. 1321-1328.
12. Savitsky, N., and W. Karlner. "Electroshock in the Presence of Organic Disease of the Central Nervous System," *J. Hillside Hosp.*, Vol. 2, 1953, pp. 3-6.
13. Karlner, W. "ECT of Patients with CNS Disease," *Psychosomatics*, Vol. 19, 1978, pp. 781-783.
14. Kaplan, L. A., and J. Dennis Freund. "Electroshock Therapy in Patients with Severe Organic Disease," *Ill. Med. J.*, Vol. 96, 1949, pp. 96-99.
15. Elmore, J. L., and A. A. Sugarman. "Precipitation of Psychosis during Electroshock Therapy," *Dis. Nerv. Syst.*, Vol. 36, 1975, pp. 115-117.
16. Sutherland, E. M., J. E. Oliver, and D. R. Knight. "EGG, Memory and Confusion in Dominant, Nondominant and Bitemporal ECG," *Br. J. Psychiatry*, Vol. 115, 1969, pp. 1059-1064.
17. Abrams, R., M. Fink, R. L. Dornbush, S. Feldstein, J. Bolavka, and J. Roubicek. "Unilateral and Bilateral Electroconvulsive Therapy," *Arch. Gen. Psychiatry*, Vol. 27, 1973, pp. 88-91.
18. Kalinowsky, L. B., and P. H. Hoch. *Somatic Treatments in Psychiatry*, pp. 147-148. Grune & Stratton, New York, 1961.



J. MARSHALL



N. KALIN



A. TARIOT

At the time this report was written all three authors were associated with the Department of Psychiatry and Center for Health Sciences at the University of Wisconsin at Madison. Dr. John R. Marshall remains there as Professor of Psychiatry along with Dr. Alice M. Tariot, Resident in Psychiatry. Dr. Ned G. Kalin is now a Clinical Associate at the National Institute for Mental Health.

## GREENBLATT (continued from page 14)

3. Bunker, H.A. "American Psychiatric Literature during the Past One Hundred Years," *One Hundred Years of American Psychiatry*, pp. 201-203. American Psychiatric Association, Columbia University Press, 1944.
4. Greenblatt, M., R.H. York, and E.L. Brown. *From Custodial to Therapeutic Patient Care in Mental Hospitals*. Russell Sage Foundation, New York, 1955.
5. Soloff, P.H. "Physical Restraint and the Nonpsychotic Patient: Clinical and Legal Perspectives," *J. Clin. Psychiatry*, Vol. 40, No. 7, 1979, pp. 302-305.
6. Sifneos, P.E. "Patient Management," *The Harvard Guide to Modern Psychiatry*, Armand M. Nicholi, Jr., ed., p. 488. The Belknap Press of Harvard University Press, Cambridge, Massachusetts, 1978.
7. Favell, J.E., J.F. McGimsey, and M.L. Jones. "The Use of Physical Restraint in the Treatment of Self-injury and as Positive Reinforcement," *J. Appl. Behav. Anal.*, Vol. 11, Summer 1978, pp. 225-241.
8. Rosen, H., and J.N. Di Giacomo. "The Role of Physical Restraint in the Treatment of Psychiatric Illness," *J. Clin. Psychiatry*, Vol. 39, No. 3, March 1978, pp. 228-232.
9. Soloff, P.H. "Behavioral Precipitants of Restraint in the Modern Milieu," *Compr. Psychiatry*, Vol. 19, No. 2, March/April 1978, pp. 179-184.
10. Schwab, P.J., and C.B. Lahmeyer. "The Uses of Seclusion on a General Hospital Psychiatric Unit," *J. Clin. Psychiatry*, Vol. 40, No. 5, May 1979, pp. 41-43, 47.
11. Lion, J.R., L.C. Levenberg, and R.E. Strange. "Restraining the Violent Patient," *J. Psychiatr. Nurs.*, Vol. 10, No. 2, March 1972, pp. 9-11.
12. Wells, D.A. "The Use of Seclusion on a University Hospital Psychiatric Floor," *Arch. Gen. Psychiatry*, Vol. 26, May 1972, pp. 410-413.
13. Gutheil, T.G. "Observations on the Theroretical Bases for Seclusion of the Psychiatric Inpatient," *Am. J. Psychiatry*, Vol. 135, No. 3, March 1978, pp. 325-328.
14. Wadeson, H., and W.T. Carpenter, Jr. "Impact of the Seclusion Room Experience," *J. Nerv. Ment. Dis.*, Vol. 163, No. 5, November 1976, pp. 318-328.
15. Kilgalen, R.K. "The Effective Use of Seclusion," *J. Psychiatr. Nurs.*, Vol. 15, No. 1, January 1977, pp. 22-25.
16. Guirguis, E.F. "Management of Disturbed Patients: An Alternative to the Use of Mechanical Restraints," *J. Clin. Psychiatry*, Vol. 39, No. 4, April 1978, pp. 295-299.
17. Carson, D.I. "Violence in the Hospitalized Patient," *N.A.P.P.H.J.*, Vol. 10, No. 3, Spring 1979, pp. 20-27.
18. Cubbin, J.K. "Mechanical Restraints: To Use or Not to Use?" *Nurs. Times*, Vol. 66, June 11, 1970, p. 752.



# 6-month index

## JULY/AUGUST 1979, VOL. 16 NO. 7

Current Psychiatric Research MHPG in Depression <i>Barry Blackwell, M.D.</i>	2
Third-Party Reimbursements: Countertherapeutic Considerations <i>Louise Enoch, A.C.S.W.; George Sigel, M.D.</i>	8
Biological Feedback: Some Conceptual Bridges with Analytically Oriented Psychotherapy <i>Kenneth Greenspan, M.D.</i>	17
Role Diffusion and "The Death of Psychiatry" <i>Richard C.W. Hall, M.D.; Louis A. Faillace, M.D.</i> <i>Mark Perl, M.B.B.S.</i>	21
The Rise and Fall of the Community Mental Health Center <i>Daniel Lieberman, M.D.</i>	31
Continuing Medical Education: What Works Best? <i>Richard S. Wilbur, M.D.</i>	41
Case Report 85: Failure in Treatment of a Borderline Patient <i>Levon D. Tashjian, M.D.</i>	43

## SEPTEMBER 1979, VOL. 16 NO. 8

The Evidence against the Catecholamine Hypothesis <i>Boo N. Chiong, M.D.</i>	10
The American Family during Inflationary Times <i>Colleen L. Johnson, Ph.D.</i>	13
Women in the Labor Force: Some Mental Health Implications <i>Doreen E. Schechter, M.D.</i>	17
Psychosomatic Medicine for the Psychiatrist <i>Milton Rosenbaum, M.D.</i>	26
Biofeedback and Future Directions of Psychiatry <i>Kenneth R. Gaarder, M.D.</i>	29
Case Report 86: "A Real Headache" <i>Joel J. Silverman, M.D.</i>	35
Current Psychiatric Research The Three Categories of Depression <i>Joseph Wolpe, M.D.</i>	43

## OCTOBER 1979, VOL. 16 NO. 9

Current Psychiatric Research The Endorphins <i>Barry Blackwell, M.D.</i>	8
Vicissitudes of Father and Daughter Relations in Single-Parent Families <i>Irving N. Berlin, M.D.</i>	9
Time Bomb in the Psychiatric Hour <i>Harvey Shwed, M.D.</i>	15
The Schizoid's Contributions to Therapy <i>Eugene C. McDonald, Jr., M.D.</i>	17
Biofeedback in Clinical Psychiatric Practice <i>Sidney Lecker, M.D.</i>	25
Case Report 87: Cerebral Palsy in Early Adolescence: A Developmental Crunch <i>John A. Chiles, M.D.; Patricia Lipscomb, M.D.</i>	29

## NOVEMBER/DECEMBER 1979, VOL. 16 NO. 10

Current Psychiatric Research Childhood Sexuality <i>E. James Anthony, M.D.</i>	11
Changing Male Roles: Its Relevance to Psychiatrists <i>Norman B. Levy, M.D.</i>	12
The Decline of Manhood: Adaptive Trend or Temporary Confusion? <i>Wolfgang Lederer, M.D.</i>	14
The Abandoned Husband: When Wives Leave <i>Ellen Halle, M.M.H.</i>	18
Postparental Fathers in Distress <i>Robert A. Lewis, Ph.D.; Craig L. Roberts, M.E.E.</i>	27
Homosexual Labelling and Cultural Control: The Role of Psychiatry <i>Michael W. Ross, Ph.D.; Annikki Talikka, Dr. Soc. Sci.</i>	31
The Community Psychiatrist as Public Defender <i>Robert D. Miller, M.D., Ph.D.</i>	34
Interface between Psychiatry and Neurology Borderlands or Desert? <i>Vernon Mark, M.D., F.A.C.S.</i>	39
Case Report 88: Lithium Response of a Patient Diagnosed as a Paranoid Schizophrenic <i>Herbert Wagemaker, Jr., M.D.</i> <i>Steven Lippmann, M.D.; David R. Bryant</i>	45

## JANUARY 1980, VOL. 17 NO. 1

Forced Termination of Psychotherapy: The Annually Recurrent Trauma <i>Paul A. DeWald, M.D.</i>	13
The Clinical Utility of Dreams in Termination <i>Jesse O. Cavenar, Jr., M.D.</i>	16
Termination of Treatment with Children <i>Heiman van Dam, M.D.; Machiel van Dam, M.A.</i>	19
The Social Breakdown Syndrome Revisited: Psychogenic Staff-Patient Relationships <i>Mark Perl, M.B.B.S.; Richard C.W. Hall, M.D.</i> <i>Earl R. Gardner, Ph.D.; Sondra K. Stickney, R.N.</i>	23
The Interface between Psychiatry and Neurology <i>Thomas H. Glick, M.D.</i>	27
A Different View of Nosology <i>Harold A. Rashkis, M.D., Ph.D.</i>	28
Current Psychiatric Research <i>Joseph Wolpe, M.D.</i>	32
Case Report 89: The Hyperactive Child With Primary Emotional Problems <i>Thomas P. Cornwall, M.D.; David F. Freeman, M.D.</i>	35

ANSWERS TO CASE REPORT SELF-ASSESSMENT (page 37): (1) a,b,d; (2) a,d; (3) b,d; (4) b; (5) d; (6) c,d.